Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas

Nature

Volumn 445, Issue 7128, 2007, Pages 656-660

  Xue, Wen ^a   Zender, Lars ^a   Miething, Cornelius ^a   Dickins, Ross A ^a,b   Hernando, Eva ^c   Krizhanovsky, Valery ^a   Cordon Cardo, Carlos ^c   Lowe, Scott W ^a,b  

^a Howard Hughes Medical Institute Cold Spring Harbor Laboratory Cold Spring Harbor   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

CANCER; CHEMOTHERAPY; DNA; IMMUNE RESPONSE; IMMUNE SYSTEM; MUTATION; RNA; SENESCENCE; TUMOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL AGING; CELL CYCLE ARREST; CELL DIFFERENTIATION; CONTROLLED STUDY; IMMUNE RESPONSE; INNATE IMMUNITY; LIVER CARCINOGENESIS; LIVER CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; RNA INTERFERENCE; TUMOR GROWTH; TUMOR REGRESSION; TUMOR SUPPRESSOR GENE; UPREGULATION;

MURINAE;

EID: 33846937033     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature05529     Document Type: Article

References (30)

1. Harris, S. L. & Levine, A. J. The p53 pathway: positive and negative feedback loops. Oncogene 24, 2899-2908 (2005).
2. Sherr, C. J. Principles of tumor suppression. Cell 116, 235-246 (2004).
3. Lowe, S. W., Cepero, E. & Evan, G. Intrinsic tumour suppression. Nature 432, 307-315 (2004).
4. Zender, L. et al. Generation and analysis of genetically defined liver carcinomas derived from bipotential liver progenitors. Cold Spring Harb. Symp. Quant. Biol. 70, 251-261 (2005).
5. Zender, L. et al. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 125, 1253-1267 (2006).
6. Staib, F., Hussain, S. P., Hofseth, L. J., Wang, X. W. & Harris, C. C. TP53 and liver carcinogenesis. Hum. Mutat. 21, 201-216 (2003).
7. Dickins, R. A. et al. Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. Nature Genet. 37, 1289-1295 (2005).
8. Silva, J. M. et al. Second-generation shRNA libraries covering the mouse and human genomes. Nature Genet. 37, 1281-1288 (2005).
9. Chin, L. et al. Essential role for oncogenic Ras in tumour maintenance. Nature 400, 468-472 (1999).
10. Jain, M. et al. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science 297, 102-104 (2002).
11. Braig, M. et al. Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 436, 660-665 (2005).
12. Chen, Z. et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436, 725-730 (2005).
13. Collado, M. et al. Tumour biology: senescence in premalignant tumours. Nature 436, 642 (2005).
14. E600-associated senescence-like cell cycle arrest of human naevi. Nature 436, 720-724 (2005).
15. INK4a. Cell 88, 593-602 (1997).
16. Minamino, T. et al. Ras induces vascular smooth muscle cell senescence and inflammation in human atherosclerosis. Circulation 108, 2264-2269 (2003).
17. Shelton, D. N., Chang, E., Whittier, P. S., Choi, D. & Funk, W. D. Microarray analysis of replicative senescence. Curr. Biol. 9, 939-945 (1999).
18. Gorgoulis, V. G. et al. p53-dependent ICAM-1 overexpression in senescent human cells identified in atherosclerotic lesions. Lab. Invest. 85, 502-511 (2005).
19. Maeda, S., Kamata, H., Luo, J. L., Leffert, H. & Karin, M. IKKβ couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 121, 977-990 (2005).
20. Mundt, B. et al. Involvement of TRAIL and its receptors in viral hepatitis. FASEB J. 17, 94-96 (2003).
21. Hong, F. et al. β-glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells. Cancer Res. 63, 9023-9031 (2003).
22. Shultz, L. D. et al. Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J. Immunol. 154, 180-191 (1995).
23. Ghiringhelli, F., Menard, C., Martin, F. & Zitvogel, L. The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression. Immunol. Rev. 214, 229-238 (2006).
24. Ventura, A. et al. Restoration of p53 function leads to tumour regression in vivo. Nature advance online publication, doi:10.1038/nature05541 (24 January 2007).
25. Christophorou, M. A., Ringshausen, I., Finch, A. J., Swigart, L. B. & Evan, G. I. The pathological response to DNA damage does not contribute to p53-mediated tumour suppression. Nature 443, 214-217 (2006).
26. Bykov, V. J. et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nature Med. 8, 282-288 (2002).
27. Vassilev, L. T. et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844-848 (2004).
28. Gray-Schopfer, V. C. et al. Cellular senescence in naevi and immortalisation in melanoma: a role for p16? Br. J. Cancer 95, 496-505 (2006).
29. Roninson, I. B. Tumor cell senescence in cancer treatment. Cancer Res. 63, 2705-2715 (2003).
30. Krtolica, A., Parrinello, S., Lockett, S., Desprez, P. Y. & Campisi, J. Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging. Proc. Natl Acad. Sci. USA 98, 12072-12077 (2001).